Antibodies
30 July 2024
Formycon announces start of clinical phase III trial for Keytruda® biosimilar candidate FYB20630 July 2024
European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion (RVO)29 July 2024
Pipeline Review of PD-L1 x 4-1BB bispecific antibodies for tumor cell–mediated T-cell activation27 July 2024
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union25 July 2024
Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities25 July 2024
Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases24 July 2024
Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC23 July 2024
FDA Approves Samsung Bioepis’ EPYSQLI® (eculizumab-aagh) as a Biosimilar to Soliris (eculizumab)News Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports